Japanese Aerospace & Defense Stock News

TSE:5201
TSE:5201Building

A Look At AGC (TSE:5201) Valuation After New Biologics Agreement And Yokohama Facility Plans

AGC stock in focus after expanded biologics agreement AGC (TSE:5201) has come into focus after AGC Biologics expanded its manufacturing agreement with Novelty Nobility and advanced plans for a new large scale biologics facility in Yokohama, Japan. The latest agreement extends work on a bispecific antibody drug candidate, progressing from successful cell line development in Copenhagen to process development and GMP manufacturing in Chiba, supported by AGC Biologics’ integrated global...
TSE:6861
TSE:6861Electronic

Assessing Keyence (TSE:6861) Valuation After Strong Full Year 2026 Earnings Results

Earnings event puts fresh focus on Keyence stock Keyence (TSE:6861) has drawn fresh attention after reporting full year 2026 results, with sales of ¥1,169,289 million and net income of ¥445,185 million compared to the prior year. See our latest analysis for Keyence. The earnings announcement and board updates have coincided with a sharp shift in sentiment, with a 1 day share price return of 7.24% and 30 day share price return of 32.44%. The 5 year total shareholder return of 47.62% points to...
TSE:3382
TSE:3382Consumer Retailing

Assessing Seven & i Holdings (TSE:3382) Valuation After Recent Share Price Weakness

What recent performance says about Seven & i Holdings With no single headline event driving trading, Seven & i Holdings (TSE:3382) has drawn attention after a 2.5% move over the past day, contrasting with weaker returns over the past month. See our latest analysis for Seven & i Holdings. The latest 2.5% 1 day share price gain to ¥1,918.5 comes after a weaker patch, with a 30 day share price return of a 12.0% decline and a 1 year total shareholder return of an 11.66% decline, indicating...
TSE:7013
TSE:7013Machinery

Does IHI’s Global Ammonia Boiler Retrofit Deal Shift The Bull Case For IHI (TSE:7013)?

In April 2026, Babcock Power Services Inc., Riley Power Inc., and IHI Corporation signed a collaboration agreement to convert existing power plant boilers worldwide to low-carbon fuels, especially ammonia, drawing on IHI’s ammonia combustion work in Japan and Indonesia. The deal highlights IHI’s growing role as a technology partner for decarbonizing legacy thermal power assets using ammonia co-firing and fuel conversion solutions. Now we’ll examine how this ammonia-focused retrofit...
TSE:9301
TSE:9301Infrastructure

Mitsubishi Logistics (TSE:9301) Valuation After Dividend Hike And Shareholder Return Plan

Mitsubishi Logistics (TSE:9301) has put shareholder returns in focus after its recent board meeting to approve a surplus dividend, tying a higher year end payout to a longer term dividend on equity target. See our latest analysis for Mitsubishi Logistics. The share price has moved to ¥1,409, with a 9.56% 90 day share price return and a 15.40% year to date share price return. The 1 year total shareholder return of 44.50% and 5 year total shareholder return of 145.10% point to solid longer term...
TSE:4523
TSE:4523Pharmaceuticals

How Investors Are Reacting To Eisai (TSE:4523) Leaning On Leqembi After Fresh Sales Update

Eisai Co., Ltd. recently reported preliminary first-quarter 2026 sales of ¥26.2 billion, alongside fiscal 2025 revenue of ¥88 billion from its Alzheimer’s drug Leqembi, underscoring the scale of its neurology operations. This combination of strong Leqembi revenue and fresh quarterly sales data highlights how Eisai’s neuroscience focus is increasingly anchored by a single high-impact Alzheimer’s therapy. Next, we’ll examine how Leqembi’s ¥88 billion revenue contribution and the latest...
TSE:9021
TSE:9021Transportation

West Japan Railway (TSE:9021) Valuation Check After Strong FY 2026 Sales And Earnings

Full year 2026 results set the tone for West Japan Railway West Japan Railway (TSE:9021) has drawn fresh attention after reporting full year results to March 31, 2026, with sales of ¥1,845,840 million and net income of ¥127,499 million. Basic earnings per share from continuing operations came in at ¥277.73. Investors now have a new reference point ahead of the company’s 2026 earnings call scheduled for May 1. See our latest analysis for West Japan Railway. At a share price of ¥2,857.0, West...
TSE:8053
TSE:8053Trade Distributors

Assessing Sumitomo (TSE:8053) Valuation After Buyback, Stock Split, Higher Dividend And New Medium Term Plan

Why Sumitomo’s latest announcements matter for shareholders Sumitomo (TSE:8053) has moved center stage after a cluster of shareholder focused decisions, including a sizeable share buyback, a four for one stock split, a higher dividend, and fresh medium term targets. See our latest analysis for Sumitomo. The stock’s recent surge appears closely tied to this cluster of shareholder focused moves, with a 1 day share price return of 17.12% and a year to date share price return of 22.82%. The 1...
TSE:1946
TSE:1946Construction

Top Dividend Stocks In Global To Consider

As global markets navigate a complex landscape of steady interest rates, geopolitical tensions, and robust corporate earnings, investors are keenly observing the performance of major indices like the S&P 500 and Nasdaq Composite, which have shown impressive gains. In this dynamic environment, dividend stocks present an attractive option for those seeking income stability amidst market volatility; these stocks often belong to companies with strong fundamentals that can weather economic...
TSE:8035
TSE:8035Semiconductor

A Look At Tokyo Electron (TSE:8035) Valuation After Strong AI-Driven Guidance And Recent Earnings Growth

Why Tokyo Electron stock is in focus after fresh guidance Tokyo Electron (TSE:8035) drew investor attention after issuing earnings guidance for the first half of the fiscal year that came in above market expectations, linked to AI related demand and customer capacity expansion. See our latest analysis for Tokyo Electron. The above consensus guidance has come alongside a 1 day share price return of 6.89% and a 30 day share price return of 23.50%. The 1 year total shareholder return of 128.83%...
TSE:3407
TSE:3407Chemicals

Is Asahi Kasei’s New ¥200bn Bond Shelf And AK1940 Trial Altering The Investment Case For Asahi Kasei (TSE:3407)?

In April 2026, Asahi Kasei Corporation filed a new ¥200,000,000,000 bond shelf registration and withdrew its prior 2020 bond shelf, while also advancing its pharmaceutical pipeline by starting a Phase I trial in Japan for AK1940, a novel peptide-based TNF receptor 1 antagonist targeting autoimmune diseases. This combination of refreshed funding flexibility and clinical progress highlights how Asahi Kasei is aligning its balance sheet and research efforts around pharmaceuticals as a core...
TSE:6098
TSE:6098Professional Services

A Look At Recruit Holdings (TSE:6098) Valuation As Board Weighs Future Share Repurchases

Board meeting on share repurchases puts Recruit Holdings in focus Recruit Holdings (TSE:6098) has called a board meeting for March 31, 2026, to decide on the status of its share repurchase plans, an item that often shapes how investors think about capital allocation. See our latest analysis for Recruit Holdings. At a share price of ¥7,361, Recruit Holdings has a 30 day share price return of 6.04%, while the year to date share price return of 18.39% and 1 year total shareholder return of...
TSE:3003
TSE:3003Real Estate

Will Hulic’s Strong Q1 2026 Revenue and EPS Gains Change Hulic's (TSE:3003) Narrative

Hulic Co., Ltd. recently reported first-quarter 2026 results, with sales rising to ¥226,841 million from ¥156,644 million and net income increasing to ¥18,141 million from ¥17,175 million a year earlier. Earnings per share from continuing operations also improved, suggesting that Hulic converted its higher revenue base into slightly stronger profitability for shareholders. We’ll now examine how Hulic’s robust year-over-year sales growth informs the company’s investment narrative and...
TSE:6728
TSE:6728Semiconductor

Does ULVAC’s Japan Furnace Expansion For Non‑China Magnets Change The Bull Case For ULVAC (TSE:6728)?

Earlier in 2026, ULVAC reported that orders for its continuous vacuum melting furnaces for rare-earth magnets are expected to roughly triple year on year, driven mainly by magnet manufacturers in Europe and North America building supply chains outside China. To capture this shift and reduce supply risk, ULVAC is adding a new production system in Japan, creating a dual-site furnace supply structure alongside its existing Chinese facility and placing itself at the center of emerging rare-earth...
TSE:5333
TSE:5333Machinery

NGK (TSE:5333) Is Up 15.7% After Solid FY2026 Earnings And Buyback Review Has The Bull Case Changed?

NGK Corporation recently reported full-year results for the period ended March 31, 2026, with sales of ¥670,125 million and net income of ¥59,936 million, and held a board meeting on April 30, 2026 to review the results of its share repurchase program. An interesting aspect of this update is the combination of solid reported earnings per share of about ¥206 and active capital management through the acquisition of its own shares. With these earnings figures and the share buyback review in...
TSE:6701
TSE:6701IT

Assessing NEC (TSE:6701) Valuation After Strong Full Year Earnings Results

Earnings snapshot and why this matters for NEC shareholders NEC (TSE:6701) has drawn fresh attention after reporting full year results to 31 March 2026, with sales of ¥3,582,733 million and net income of ¥270,228 million, alongside higher basic and diluted EPS from continuing operations. For existing and potential shareholders, these figures give an updated view of how NEC is converting its information technology and social infrastructure business into earnings, and how each share is...
TSE:4151
TSE:4151Pharmaceuticals

Kyowa Kirin (TSE:4151) Valuation Check As Ziftomenib Trial In Japan Reaches First Patient Milestone

Kyowa Kirin (TSE:4151) has dosed the first patient in a Japanese Phase 2 registrational trial of ziftomenib for relapsed or refractory NPM1 mutated acute myeloid leukemia, following the drug’s prior U.S. approval. See our latest analysis for Kyowa Kirin. The first patient dosing in Japan comes after a busy period for Kyowa Kirin, with conference appearances and product progress coinciding with a 12% one year total shareholder return, even as the 30 day share price return of a 7.94% decline...